

A woman with long brown hair, wearing a blue long-sleeved shirt, blue jeans, and a white and purple cast on her right leg, is walking a brown dog on a leash. They are in a park-like setting with tall grass, a large tree with green and yellowing leaves, and a chain-link fence in the background. The scene is lit with warm, golden light, suggesting late afternoon or early morning.

Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023

enovis™

Forward -looking Statements

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, including the anticipated benefits of the recently completed spin-off of ESAB Corporation into an independent publicly traded company (the "Separation") and other statements that are not historical or current fact. Forward-looking statements are based on Enovis' current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis' results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the scope and duration of the outbreak, the rise, prevalence and severity of variants of the virus, material delays and cancellations of medical procedures, the nature and effectiveness of actions and restrictive measures by governments, businesses and individuals in response to the situation, and their impact on the global and regional economies, financial markets, creditworthiness and financial viability of customers, and overall demand for our products; the war in Ukraine and escalating geopolitical tensions as a result of Russia's invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; the potential to incur significant liability if the Separation is determined to be a taxable transaction; the ability to realize the anticipated benefits of the Separation, the financial and operating performance of the company following the Separation; other impacts on Enovis' business and ability to execute business continuity plans; and the other factors detailed in Enovis' reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as the other risks discussed in Enovis' filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Non-GAAP Financial Information

Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income per diluted share from continuing operations, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA margin and organic sales growth. Adjusted net income from continuing operations and adjusted net income per diluted share from continuing operations exclude restructuring and other charges, European Union Medical Device Regulation ("MDR") and other costs, amortization of acquired intangibles, inventory step-up costs, strategic transaction costs, debt extinguishment charges, insurance settlement gain, gains and losses on the Company's investments, stock compensation costs and other income. Adjusted net income adjusts interest expense to reflect pro forma interest from the Company's term loan facility under the Company's current capital structure after giving effect to the completing of the refinancing transactions in connection with the Separation, and it includes the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations. Adjusted EBITDA represents operating income from continuing operations excluding restructuring and other charges, MDR and other costs, strategic transaction costs, stock-based compensation costs, depreciation and amortization, amortization of acquired intangibles, insurance settlement gain, and inventory step up costs. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Organic sales growth excludes the impact of acquisitions and foreign exchange rate fluctuations. Sales per day growth includes the same adjustments as Organic sales growth and adjusts for the number of selling days in the period. These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this presentation. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.

2022 Recap

Strategic Pillars:

Shape P&R for sustained MSD growth

Outpaced peers with 3.5% sales per day growth

Improved service levels and expanded MotionMD® platform

Rapidly Expand High Growth & Margin Recon Platform

Double-Digit growth across anatomies

Global expansion through Mathys underway

Expand Margins With EGX & Scale

Improved aEBITDA margins by 70 bps amid inflation and FX pressure

Corporate cost reductions of ~\$25mm and pricing discipline

Accelerate Growth Through M&A

Recent acquisitions grew double-digits and started to scale

Enhanced emerging technology capability through acquisitions: e.g. ARVIS™ surgical navigation system and 360 Med Care

Successful first year as a focused Med-Tech growth company with +10% growth (+6% organic)

Q4 2022 Highlights




- **Achieved organic growth of 5%**
 - Strong DD growth in Recon globally
 - LSD growth in P&R, impacted by slower than normal clinic volume
- **Expanded adjusted EBITDA margins 290 basis points**
 - Inflation and FX stabilized
 - Solid operating expense controls
- **Continued EGX momentum**
 - Safety and service levels continue to improve
 - Supply chain resiliency & acquisition scaling

Solid Q4 performance and strong finish to the year

Q4 Reconstructive Segment Sales Performance

Reconstructive Q4 Sales

Growth: Organic sales +14%; total reported sales +12%



- **Double-digit US growth**
 - Knees & hips organic growth of 14%
 - Extremities organic growth of 13%, led by shoulder
- **Mathys organic growth of 16%, momentum building for growth synergies**
- **Continued innovation momentum**
 - EMPOWR™ Revision Knee
 - DynaClip® Delta™ & Quattro™
 - Patient Specific Instrumentation for STAR® Ankle

Demonstrating sustainable DD growth

Q4 Prevention & Recovery Segment Sales Performance

P&R Q4 Sales

Growth: Organic sales +1%; total reported -2%



- **Full year sales per day growth of 3.5%**
 - Q4 US clinic volumes slowed temporarily
 - >4% full year global bracing growth reflects market share gain
- **Improved service levels**
 - Finished with backlog at multi-year low
- **Strong growth in MotionMD™ clinic workflow solutions**
 - >30% growth in installed clinic locations, supporting customers with best-in-class workflow and billing solutions

Continue to improve and shape P&R

P&L Performance

<i>millions</i>	<u>Q4 2021</u>	<u>Q4 2022</u>
Net Sales	\$399	\$409
Adj. Gross Profit Margin	\$220 55.2%	\$233 57.1%
Adj. EBITDA Margin	\$62 15.4%	\$75 18.3%
Adj. EPS	\$0.81	\$0.72

- Margins up +290 bps
- >20% operating EPS growth when adjusting for positive tax items in 2021

<i>millions</i>	<u>FY 2021</u>	<u>FY 2022</u>
Net Sales	\$1,426	\$1,563
Adj. Gross Profit Margin	\$794 55.6%	\$884 56.5%
Adj. EBITDA Margin	\$206 14.4%	\$236 15.1%
Adj. EPS	\$1.97	\$2.27


- +10% sales growth, +6% organic, led by Recon
- +15% aEBITDA and aEPS growth

Solid growth in Q4 and Full Year


Full Year 2022 Progression

Organic sales per day growth vs. 2021 (% , constant currency)

enovis.



Recon




P&R




- Double-digit Recon performance
- Solid P&R performance through 9 months, short-term market pressure in Q4

aEBITDA margin (%)



aEBITDA margin bridge vs. 2021 (%)



- Sequential margin improvement over the course of the year
- \$25mm of FY cost reductions and H2 price/cost stabilization driving operating performance

Delivered strong results in dynamic environment

Full Year 2023 Outlook

	2022 Results	2023 Outlook	Comments
Organic Sales Growth	6% (cc)	5-6% (cc)	<ul style="list-style-type: none"> Global markets grow in line with historical averages; DD recon growth continues
aEBITDA	\$236mm	\$255-\$265mm	
Depreciation¹	\$77mm	~\$85mm	<ul style="list-style-type: none"> ≥50 bps margin improvement; quarterly margin phasing similar to 2022
Interest Expense	\$12mm	~\$23mm	
Effective Tax Rate	15.9%	~20%	<ul style="list-style-type: none"> Exchange rates in-line with early 2023, H1 headwind
aEPS	\$2.27	\$2.15-\$2.30	

Another year of strong growth and margin expansion

Summary



- Strong first year of performance as a focused, independent med-tech growth company
- Creating momentum for a high-single-digit growth engine fueled by innovation
- Significant margin improvement path through mix, productivity and scale
- Acquisition opportunities and ample capital to accelerate growth and compound value

Appendix



enovis[™]

Creating Better Together[™]

QTD and YTD Enovis Sales Bridge

Enovis Corporation
Reconciliation of GAAP to non-GAAP Financial Measures
Change in Sales
Dollars in millions
(Unaudited)

	Net Sales					
	Prevention and Recovery		Reconstructive		Total Enovis	
	\$	Change %	\$	Change %	\$	Change %
For the three months ended December 31, 2021	\$ 268.2		\$ 130.8		\$ 399.0	
<i>Components of Change:</i>						
Existing businesses ⁽¹⁾	3.1	1.2 %	17.7	13.5 %	20.8	5.2 %
Acquisitions ⁽²⁾	—	— %	1.3	1.0 %	1.3	0.3 %
Foreign currency translation ⁽³⁾	(8.8)	(3.3)%	(3.6)	(2.8)%	(12.4)	(3.1)%
	(5.7)	(2.1)%	15.4	11.8 %	9.7	2.4 %
For the three months ended December 31, 2022	<u>\$ 262.6</u>		<u>\$ 146.2</u>		<u>\$ 408.7</u>	

⁽¹⁾ Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.

⁽²⁾ Represents the incremental sales as a result of acquisitions closed subsequent to the beginning of the prior year period.

⁽³⁾ Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

	Net Sales					
	Prevention and Recovery		Reconstructive		Total Enovis	
	\$	Change %	\$	Change %	\$	Change %
For the year ended December 31, 2021	\$ 1,026.0		\$ 400.2		\$ 1,426.2	
<i>Components of Change:</i>						
Existing businesses ⁽¹⁾	32.5	3.2 %	47.1	11.8 %	79.6	5.6 %
Acquisitions ⁽²⁾	—	— %	93.3	23.3 %	93.3	6.5 %
Foreign currency translation ⁽³⁾	(30.9)	(3.0)%	(5.1)	(1.3)%	(36.0)	(2.5)%
	1.6	0.2 %	135.3	33.8 %	136.9	9.6 %
For the year ended December 31, 2022	<u>\$ 1,027.6</u>		<u>\$ 535.5</u>		<u>\$ 1,563.1</u>	

⁽¹⁾ Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.

⁽²⁾ Represents the incremental sales as a result of acquisitions closed subsequent to the beginning of the prior year period.

⁽³⁾ Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

QTD and YTD Enovis aEPS Reconciliation

Reconciliation of GAAP to Non-GAAP Financial Measures Dollars in millions, except per share data (Unaudited)

	Three Months Ended		Year Ended	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Adjusted Net Income and Adjusted Net Income Per Share				
Net loss from continuing operations attributable to Enovis Corporation ⁽¹⁾ (GAAP)	\$ (54.9)	\$ (14.9)	\$ (38.8)	\$ (103.3)
Restructuring and other charges - pretax ⁽²⁾	10.5	8.7	19.0	13.9
MDR and related costs - pretax ⁽³⁾	6.1	2.4	16.7	7.9
Amortization of acquired intangibles - pretax	31.7	28.9	126.3	116.9
Inventory step-up - pretax	0.8	7.1	12.8	10.8
Strategic transaction costs - pretax ⁽⁴⁾	28.5	7.7	61.0	23.4
Debt extinguishment charges - pretax	0.3	—	20.4	29.9
Pro forma interest expense adjustment ⁽⁵⁾	1.5	5.4	12.5	25.1
Insurance settlement gain ⁽⁶⁾	(4.6)	—	(36.7)	—
Gain on investment in ESAB Corporation	(30.3)	—	(102.7)	—
Gain on cost basis investment	—	—	(8.8)	—
Stock-based compensation	9.8	6.7	31.5	25.7
Other income	(1.8)	—	(2.1)	—
Tax adjustment ⁽⁷⁾	41.6	(7.6)	12.6	(48.5)
Adjusted net income from continuing operations (non-GAAP)	\$ 39.1	\$ 44.2	\$ 123.7	\$ 101.9
Adjusted net income margin from continuing operations	9.6 %	11.1 %	7.9 %	7.1 %
Weighted-average shares outstanding - diluted (in thousands)	54,630	54,458	54,503	51,847
Adjusted net income per share - diluted from continuing operations (non-GAAP)	\$ 0.72	\$ 0.81	\$ 2.27	\$ 1.97
Net loss per share - diluted from continuing operations (GAAP)	\$ (1.01)	\$ (0.28)	\$ (0.72)	\$ (2.02)

⁽¹⁾ Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of \$0.0 million and \$0.6 million for the three months and year ended December 31, 2022, respectively, and \$0.2 million and \$1.1 million for the three months and year ended December 31, 2021, respectively.

⁽²⁾ Restructuring and other charges includes \$0.9 million and \$1.7 million of expense classified as Cost of sales on our Consolidated Statements of Operations for the three months and year ended December 31, 2022, respectively, and \$5.2 million of expense classified as Cost of sales on our Consolidated Statements of Operations for the three months and year ended December 31, 2021, respectively.

⁽³⁾ Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017 ("MDR"). These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

⁽⁴⁾ Strategic transaction costs includes costs related to the Separation and certain transaction and integration costs related to recent acquisitions.

⁽⁵⁾ Adjusts interest expense to reflect pro forma interest from the Company's term loan facility under the Company's current capital structure after giving effect to the completion of the refinancing transactions in connection with the Separation and is applied to all periods presented for the comparability of results.

⁽⁶⁾ Insurance settlement gain relates to the Company's 2019 acquisition of DJO.

⁽⁷⁾ The effective tax rates used to calculate adjusted net income and adjusted net income per share were 21.4% and 15.9% for the three months and year ended December 31, 2022, respectively, and (5.3)% and 22.0% for the three months and year ended December 31, 2021, respectively.

QTD and YTD Enovis aEBITDA Reconciliation

Reconciliation of GAAP to Non-GAAP Financial Measures

Dollars in millions
(Unaudited)

	Three Months Ended					Year Ended	
	December 31, 2021	April 1, 2022	July 1, 2022	September 30, 2022	December 31, 2022	December 31, 2021	December 31, 2022
Net (loss) income from continuing operations (GAAP) ⁽¹⁾	\$ (14.7)	\$ (38.1)	\$ 120.7	\$ (65.9)	\$ (54.8)	\$ (102.3)	\$ (38.2)
Income tax expense (benefit)	(9.9)	0.4	(4.2)	(12.3)	52.3	(19.5)	36.1
Other income	—	—	—	(0.3)	(1.8)	—	(2.1)
Gain on cost basis investment	—	—	—	(8.8)	—	—	(8.8)
(Gain) loss on investment in ESAB Corporation	—	—	(135.5)	63.1	(30.3)	—	(102.7)
Debt extinguishment charges	—	—	20.1	—	0.3	29.9	20.4
Interest expense, net	6.4	7.1	4.5	6.3	6.1	29.1	24.1
Operating (loss) income (GAAP)	(18.2)	(30.6)	5.6	(17.9)	(28.2)	(62.8)	(71.2)
Adjusted to add (deduct):							
Restructuring and other charges ⁽¹⁾	8.7	2.9	2.6	3.0	10.5	13.9	19.0
MDR and other costs ⁽²⁾	2.4	2.6	4.4	3.6	6.1	7.9	16.7
Strategic transaction costs ⁽³⁾	7.7	11.7	12.7	8.1	28.5	23.4	61.0
Stock-based compensation	6.7	6.7	7.8	7.2	9.8	25.7	31.5
Depreciation and other amortization	18.4	18.5	19.5	18.2	20.6	70.1	76.7
Amortization of acquired intangibles	28.9	30.8	31.8	32.0	31.7	116.9	126.3
Insurance settlement (gain) loss ⁽⁴⁾	—	—	(33.0)	1.0	(4.6)	—	(36.7)
Inventory step-up	7.1	5.1	4.9	2.1	0.8	10.8	12.8
Adjusted EBITDA (non-GAAP)	\$ 61.6	\$ 47.7	\$ 56.2	\$ 57.2	\$ 74.9	\$ 206.0	\$ 236.1
Adjusted EBITDA margin (non-GAAP)	15.4 %	12.7 %	14.2 %	14.9 %	18.3 %	14.4 %	15.1 %

⁽¹⁾ Restructuring and other charges includes \$5.2 million, \$0.5 million, \$0.3 million, \$0.0 million, and \$0.9 million of expense classified as Cost of sales on our Consolidated Statements of Operations for the three months ended December 31, 2021, April 1, 2022, July 1, 2022, September 30, 2022, and December 31, 2022, respectively, and \$5.2 million and \$1.7 million for the years ended December 31, 2021 and December 31, 2022, respectively.

⁽²⁾ Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

⁽³⁾ Strategic transaction costs includes costs related to the Separation and certain transaction and integration costs related to recent acquisitions.

⁽⁴⁾ Insurance settlement (gain) loss relates to the Company's 2019 acquisition of DJO.

Q4'22 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions

	Enovis Continuing Operations	Acquisition- Related Non-cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Debt and Investment Adjustments ^d	Income Tax Adjustment ^e	Adjusted
Net sales	\$ 408.7	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 408.7
Cost of goods sold	177.0	(0.8)	(0.9)	-	-	-	175.3
Gross profit	231.8	0.8	0.9	-	-	-	233.4
<i>Gross margin</i>	56.7%						57.1%
Selling, general and administrative expense	208.6	-	-	(44.3)	-	-	164.3
Research and development expense	14.7	-	-	-	-	-	14.7
Amortization of acquired intangibles	31.7	(31.7)	-	-	-	-	-
Insurance settlement gain	(4.6)	-	-	4.6	-	-	-
Restructuring and other charges	9.6	-	(9.6)	-	-	-	-
Operating (loss) income	(28.2)	32.5	10.5	39.6	-	-	54.4
Interest expense, net	6.1	-	-	-	(1.5)	-	4.6
Debt extinguishment charges	0.3	-	-	-	(0.3)	-	-
Gain on investment in ESAB Corporation	(30.3)	-	-	-	30.3	-	-
Other income	(1.8)	-	-	1.8	-	-	-
(Loss) income before taxes	(2.5)	32.5	10.5	37.9	(28.5)	-	49.8
Income tax expense	52.3	-	-	-	-	(41.6)	10.7
Less: NCI income, net of taxes	0.0	-	-	-	-	-	0.0
Net (loss) income attributable to Enovis	\$ (86.6)	\$ 32.5	\$ 10.5	\$ 39.6	\$ 1.5	\$ 41.6	\$ 39.1

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$28.5, stock-based compensation expense of \$9.8 and MDR & related costs of \$6.1, insurance settlement gain, and other income.

^d Adjusts interest expense to \$4.6 to reflect a deleveraged debt structure, and removes impact of ESAB investment and debt extinguishment charges.

^e The effective tax rate used to calculate adjusted net income and adjusted net income per share was 21.4%.

Q4'21 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions

	Enovis Continuing Operations	Acquisition- Related Non-cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Debt Adjustment ^d	Income Tax Adjustment ^e	Adjusted
Net sales	\$ 399.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 399.1
Cost of goods sold	191.1	(7.1)	(5.2)	-	-	-	178.8
Gross profit	207.9	7.1	5.2	-	-	-	220.2
<i>Gross margin</i>	52.1%						55.2%
Selling, general and administrative expense	178.6	-	-	(16.8)	-	-	161.8
Research and development expense	15.2	-	-	-	-	-	15.2
Amortization of acquired intangibles	28.9	(28.9)	-	-	-	-	-
Restructuring and other charges	3.5	-	(3.5)	-	-	-	-
Operating (loss) income	(18.2)	36.0	8.7	16.8	-	-	43.1
Interest expense, net	6.4	-	-	-	(5.4)	-	1.0
(Loss) income before taxes	(24.6)	36.0	8.7	16.8	5.4	-	42.1
Income tax benefit	(9.9)	-	-	-	-	7.6	(2.2)
Less: NCI income, net of taxes	0.2	-	-	-	-	-	0.2
Net (loss) income attributable to Enovis	\$ (14.9)	\$ 36.0	\$ 8.7	\$ 16.8	\$ 5.4	\$ (7.6)	\$ 44.2

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$7.7, stock-based compensation expense of \$6.7 and MDR & related costs of \$2.4.

^d Adjusts interest expense to \$1.0 to reflect a deleveraged debt structure.

^e The effective tax rate used to calculate adjusted net income and adjusted net income per share was (5.3%).

YTD 2022 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions

	Enovis Continuing Operations	Acquisition- Related Non-cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Debt and Investment Adjustments ^d	Income Tax Adjustment ^e	Adjusted
Net sales	\$ 1,563.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,563.1
Cost of goods sold	693.7	(12.8)	(1.7)	-	-	-	679.2
Gross profit	869.4	12.8	1.7	-	-	-	883.9
<i>Gross margin</i>	55.6%						56.5%
Selling, general and administrative expense	772.9	-	-	(109.2)	-	-	663.7
Research and development expense	60.8	-	-	-	-	-	60.8
Amortization of acquired intangibles	126.3	(126.3)	-	-	-	-	-
Insurance settlement gain	(36.7)	-	-	36.7	-	-	-
Restructuring and other charges	17.2	-	(17.2)	-	-	-	-
Operating (loss) income	(71.2)	139.1	19.0	72.5	-	-	159.4
Interest expense, net	24.1	-	-	-	(12.5)	-	11.6
Debt extinguishment charges	20.4	-	-	-	(20.4)	-	-
Gain on investment in ESAB Corporation	(102.7)	-	-	-	102.7	-	-
Gain on cost basis investment	(8.8)	-	-	-	8.8	-	-
Other income	(2.1)	-	-	2.1	-	-	-
(Loss) income before taxes	(2.1)	139.1	19.0	70.4	(78.6)	-	147.8
Income tax expense	36.1	-	-	-	-	(12.6)	23.5
Less: NCI income, net of taxes	0.6	-	-	-	-	-	0.6
Net (loss) income attributable to Enovis	\$ (131.9)	\$ 139.1	\$ 19.0	\$ 72.5	\$ 12.5	\$ 12.6	\$ 123.7

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$61.0, stock-based compensation expense of \$31.5, MDR & related costs of \$16.7, insurance settlement gain, and other income.

^d Adjusts interest expense to \$11.6 to reflect a deleveraged debt structure, and removes impact of investments and debt extinguishment charges.

^e The effective tax rate used to calculate adjusted net income and adjusted net income per share was 15.9%.

YTD 2021 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions

	Enovis Continuing Operations	Acquisition- Related Non-cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustment ^c	Debt Adjustments ^d	Income Tax Adjustment ^e	Adjusted
Net sales	\$ 1,426.2	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,426.2
Cost of goods sold	648.5	(10.8)	(5.2)	-	-	-	632.5
Gross profit	777.7	10.8	5.2	-	-	-	793.7
<i>Gross margin</i>	54.5%						55.6%
Selling, general and administrative expense	665.8	-	-	(57.1)	-	-	608.6
Research and development expense	49.0	-	-	-	-	-	49.0
Amortization of acquired intangibles	116.9	(116.9)	-	-	-	-	-
Restructuring and other charges	8.7	-	(8.7)	-	-	-	-
Operating (loss) income	(62.8)	127.7	13.9	57.1	-	-	136.0
Interest expense, net	29.1	-	-	-	(25.1)	-	4.0
Debt extinguishment charges	29.9	-	-	-	(29.9)	-	-
(Loss) income before taxes	(121.7)	127.7	13.9	57.1	55.0	-	132.0
Income tax (benefit) expense	(19.5)	-	-	-	-	48.5	29.0
Less: NCI income, net of taxes	1.1	-	-	-	-	-	1.1
Net (loss) income attributable to Enovis	\$ (73.4)	\$ 127.7	\$ 13.9	\$ 57.1	\$ 25.1	\$ (48.5)	\$ 101.9

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$23.5, stock-based compensation expense of \$25.7 and MDR & related costs of \$7.9.

^d Adjusts interest expense to \$4.0 to reflect a deleveraged debt structure and removes impact of debt extinguishment charges.

^e The effective tax rate used to calculate adjusted net income and adjusted net income per share was 22.0%.

enovis™

Creating Better Together™